Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here

Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

Bookmark and Share
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
Diabetes News
Clinical trials testing therapies for diabetes

Latest Top (15) News

A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center
Condition:   Lipoprotein Disorder
Sponsors:   Huashan Hospital;   Pfizer
Not yet recruiting

Mon, 18 Oct 2021 12:00:00 EDT

Accuracy Comparison of Two CGMs in Hospitalized Patients
Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Sponsors:   University of California, San Diego;   DexCom, Inc.

Mon, 18 Oct 2021 12:00:00 EDT

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Osteoarthritis
Conditions:   Osteoarthritis;   Osteo Arthritis Knee
Interventions:   Drug: LY356318;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Not yet recruiting

Mon, 18 Oct 2021 12:00:00 EDT

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Conditions:   Interaction, Adverse Herb-Drug;   Diabetes Mellitus, Type 2
Interventions:   Drug: Midazolam Hcl 1Mg/Ml Inj;   Dietary Supplement: Goldenseal (Hydrastis canadensis)
Sponsors:   Washington State University;   National Center for Complementary and Integrative Health (NCCIH)

Mon, 18 Oct 2021 12:00:00 EDT

Clinical Trial to Evaluate Safety and Efficacy of MesoCellA-Ortho Tissue-Engineered Advanced Therapy Product in Patients With Osteoarthrosis and Civilisation Diseases
Condition:   Osteoarthritis of Knee
Interventions:   Drug: MesoCellA-Ortho administration;   Drug: HA administration
Sponsors:   Jagiellonian University;   National Center for Research and Development, Poland;   KCRI
Not yet recruiting

Mon, 18 Oct 2021 12:00:00 EDT

De-Adoption of Beta-Blockers in Patients With Stable Ischemic Heart Disease
Conditions:   Stable Ischemic Heart Disease;   Coronary Artery Disease;   Beta-blocker Therapy
Interventions:   Other: Medical Assessment;   Other: Quality of Life Assessment
Sponsor:   University of Alberta
Not yet recruiting

Mon, 18 Oct 2021 12:00:00 EDT

Evaluating Benefit of Peptide Based Diet in Obese HEN Patients
Condition:   Obesity
Intervention:   Dietary Supplement: Peptamen Intense VHP, Nestlé Health Science, Switzerland
Sponsor:   Mayo Clinic
Enrolling by invitation

Mon, 18 Oct 2021 12:00:00 EDT

Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)
Conditions:   Gestational Diabetes;   Glucose Metabolism Disorders;   Metabolic Disease
Intervention:   Device: Wearable Care Group
Sponsors:   KK Women's and Children's Hospital;   Duke-NUS Graduate Medical School;   Singapore Institute for Clinical Sciences

Mon, 18 Oct 2021 12:00:00 EDT

Stress Echo 2030: the Novel ABCDE-(FGLPR) Protocol to Define the Future of Imaging
Condition:   Coronary Artery Disease;Heart Failure;Hypertrophic Cardiomyopathy; Congenital and Valvular Heart Disease; Post-chest Radio/Chemiotherapy; Heart Transplantation
Interventions:   Diagnostic Test: ABCDE-Stress Echo;   Diagnostic Test: SE diastolic assessment;   Diagnostic Test: SE Right ventricular function assessment;   Diagnostic Test: SE in heart donors
Sponsors:   Fatebenefratelli Hospital;   Institute oif Clinical Physiology,CNR, Pisa Italy;   Mayo Clinic;   Hospital Sao Vicente de Paulo e Hospital de Cidade, Passo Fundo, Brasil;   Cardarelli Hospital, Naples, Italy;   Ospedale per gli Infermi, Faenza, Ravenna, Italy;   Institute of Family Medicine, University of Szeged, Hungary;   Montepulciano Hospital, Siena;   University of Pisa, Italy;   University Hospital, Pleven, Bulgaria;   Tomsk National Research Medical Centre of the Russian;   University Hospital, Szeged, Hungary;   Elisabeth Hospital, Hódmezővásárhely, Hungary;   DASA, San Paolo, Brasil;   University of Banja Luka University Clinical Centre of the Republic of Srpska;   University of A Coruna, La Coruna, Spain;   Antwerp University Hospital, Edegem, Belgium;   Università Luigi Vanvitelli della Campania;   Dolo Hospital, Venice, Italy;   Institute for Cardiovascular Diseases Dedinje, School of Medicine, Belgrade, Serbia;   Investigaciones Medicas, Buenos Aires, Argentina;   Bieganski Hospital, Medical University, Lodz, Poland;   Medical University of Silesia, Katowice, Poland;   Federal University of Paranà, Curitiba, Brasil;   Siriraj Hospital, Mahidol University, Bangkok, Thailand.;   Careggi Hospital, Florence;   Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico;   Saint Petersburg State University Hospital, Russian Federation;   Clinical Hospital Zvezdara, Medical School, University of Belgrade, Serbia;   University Center Serbia, Medical School, University of Belgrade, Serbia;   University Hospital, Padua, Italy;   Sant'Anna School of Advanced Study, Pisa;   University Hospital, Siena, Italy;   Vilnius University, Lithuania;   University of Parma;   University of Verona, Italy;   Malpighi Hospital, Bologna, Italy;   University of Modena and Reggio Emilia, Italy;   Presidio Ospedale San Paolo. Milano;   IRCCS Reggio Emilia, Italy.;   Association for Public Health "Salute Pubblica", Brindisi, Italy;   Catania University, Italy;   Ospedale San Camillo, Rome, Italy;   University of Salerno, Italy;   University of Algarve, Portugal.;   Heart Center, Hospital da Cruz Vermelha, Lisbon;   University of Bari;   Hospital Motta di Livenza, Treviso, Italy;   Centro Cardiologico Monzino;   Italian Society of Echocardiography and Cardiovascular Imaging;   San Luca Hospital, Lucca, Italy;   Hospital Sao José, Criciuma

Mon, 18 Oct 2021 12:00:00 EDT

The Effect of Enhanced Recovery After Surgery (ERAS) for Cesarean Section on Neonatal Blood Glucose
Conditions:   Enhanced Recovery After Surgery;   Cesarean Section
Intervention:   Dietary Supplement: Carbohydrate Preoperative Drink
Sponsor:   University of Arizona
Not yet recruiting

Mon, 18 Oct 2021 12:00:00 EDT

The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib
Condition:   Ovary Cancer
Interventions:   Drug: Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.);   Device: Lynparza
Sponsors:   Poznan University of Medical Sciences;   Poznan University Hospital of Lord's Transfiguration

Mon, 18 Oct 2021 12:00:00 EDT

A Phase 1 Study of Empagliflozin as Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Conditions:   Crohn's Disease;   Glycogen Metabolism;   Inflammatory Bowel Disease (IBD)
Intervention:   Drug: Empagliflozin
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)

Fri, 15 Oct 2021 12:00:00 EDT

Biomarker of Diabetic Retinopathy
Condition:   Diabetic Retinopathy
Intervention:   Other: Blood draw
Sponsor:   Indiana University
Not yet recruiting

Fri, 15 Oct 2021 12:00:00 EDT

Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study
Condition:   Hyperlipidemia; Mixed
Intervention:   Drug: Ezetimibe 10mg
Sponsor:   Misr University for Science and Technology
Active, not recruiting

Fri, 15 Oct 2021 12:00:00 EDT

Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment
Conditions:   Pregnancy Related;   Fertility Issues;   Luteal Phase Defect;   Infertility Unexplained
Interventions:   Drug: Progesterone Vaginal Product;   Drug: Placebo
Sponsor:   UMC Utrecht
Not yet recruiting

Fri, 15 Oct 2021 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News

FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira
The U.S. Food and Drug Administration today approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm) is now approved as interchangeable with (and may be substituted for) its reference product Humira (adalimumab).

Mon, 18 Oct 2021 10:27:40 EDT

Coronavirus (COVID-19) Update: 10/15/21
Coronavirus (COVID-19) Update

Fri, 15 Oct 2021 16:35:58 EDT

FDA to Hold Advisory Committee Meeting to Discuss Merck and Ridgeback’s EUA Application for COVID-19 Oral Treatment
The FDA is announcing an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s Application for the Emergency Use of a COVID-19 Oral Treatment

Thu, 14 Oct 2021 13:34:51 EDT

FDA Awards 11 Grants to Clinical Trials to Develop New Medical Products for Rare Disease Treatments
Today, the U.S. Food and Drug Administration announced it has awarded 11 new clinical trial research grants, equaling more than $25 million of funding over the next four years.

Thu, 14 Oct 2021 13:25:36 EDT

To Improve Nutrition and Reduce the Burden of Disease, FDA Issues Food Industry Guidance for Voluntarily Reducing Sodium in Processed and Packaged Foods
FDA Issues Final Guidance to Food Industry for Voluntarily Reducing Sodium in Processed and Packaged Foods

Wed, 13 Oct 2021 07:05:11 EDT

Coronavirus (COVID-19) Update: October 12, 2021
Coronavirus (COVID-19) Update: October 12, 2021

Tue, 12 Oct 2021 15:23:22 EDT

FDA Permits Marketing of E-Cigarette Products, Marking First Authorization of Its Kind by the Agency
FDA authorized the marketing of three new tobacco products, marking the first set of electronic nicotine delivery system (ENDS) products ever to be authorized by the agency through the Premarket Tobacco Product Application (PMTA) pathway.

Tue, 12 Oct 2021 15:22:35 EDT

FDA Approves Innovative Treatment for Pediatric Patients with Congenital Athymia
FDA approves Rethymic for immune reconstitution in pediatric patients with congenital athymia which is the first thymus tissue product approved in the U.S.

Fri, 08 Oct 2021 18:11:24 EDT

Coronavirus (COVID-19) Update: October 8, 2021
Coronavirus (COVID-19) Update

Fri, 08 Oct 2021 14:30:38 EDT

FDA In Brief: FDA Warns Public and Health Care Professionals Not to Use Needle-free Devices for Injection of Dermal Fillers
FDA is warning the public and health care professionals not to use needle-free devices commonly referred to as dermal fillers or fillers.

Fri, 08 Oct 2021 14:10:06 EDT
Diabetes news from the American Diabetes Association

Latest Top (5) News